Melissa Baird Sells 67,687 Shares of Hims & Hers Health, Inc. (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS) COO Melissa Baird sold 67,687 shares of the stock in a transaction dated Wednesday, March 26th. The stock was sold at an average price of $34.84, for a total value of $2,358,215.08. Following the transaction, the chief operating officer now directly owns 751,243 shares in the company, valued at approximately $26,173,306.12. The trade was a 8.27 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Melissa Baird also recently made the following trade(s):

• On Wednesday, February 12th, Melissa Baird sold 67,687 shares of Hims & Hers Health stock. The shares were sold at an average price of $44.71, for a total transaction of $3,026,285.77.
• On Tuesday, January 21st, Melissa Baird sold 67,687 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.35, for a total transaction of $1,986,613.45.

Hims & Hers Health Trading Down 8.8 %

Shares of HIMS opened at $29.11 on Friday. The company’s 50 day simple moving average is $39.88 and its 200-day simple moving average is $29.37. The firm has a market cap of $6.47 billion, a PE ratio of 66.15 and a beta of 1.37. Hims & Hers Health, Inc. has a 12-month low of $11.20 and a 12-month high of $72.98.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings data on Monday, February 24th. The company reported $0.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.09 by $0.02. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The company had revenue of $481.14 million for the quarter, compared to the consensus estimate of $494.56 million. As a group, equities research analysts forecast that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on HIMS. Needham & Company LLC lifted their target price on Hims & Hers Health from $31.00 to $61.00 and gave the company a “buy” rating in a report on Tuesday, February 25th. Citigroup reissued a “sell” rating and set a $27.00 price objective on shares of Hims & Hers Health in a research report on Thursday, March 6th. Leerink Partners raised their target price on shares of Hims & Hers Health from $24.00 to $40.00 and gave the company a “market perform” rating in a report on Tuesday, February 25th. Morgan Stanley cut shares of Hims & Hers Health from an “overweight” rating to an “equal weight” rating and boosted their price target for the stock from $42.00 to $60.00 in a report on Tuesday, February 18th. Finally, Bank of America increased their price objective on shares of Hims & Hers Health from $21.00 to $22.00 and gave the company an “underperform” rating in a research report on Tuesday, March 18th. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, Hims & Hers Health presently has an average rating of “Hold” and an average target price of $37.31.

Hedge Funds Weigh In On Hims & Hers Health

Institutional investors have recently added to or reduced their stakes in the stock. Crewe Advisors LLC purchased a new position in shares of Hims & Hers Health in the 4th quarter valued at approximately $28,000. Raleigh Capital Management Inc. grew its position in Hims & Hers Health by 1,100.0% in the 4th quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after buying an additional 1,100 shares during the last quarter. Blume Capital Management Inc. increased its stake in Hims & Hers Health by 100.0% in the 4th quarter. Blume Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after buying an additional 600 shares during the period. Smartleaf Asset Management LLC raised its position in Hims & Hers Health by 4,415.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company’s stock worth $36,000 after buying an additional 1,413 shares during the last quarter. Finally, Summit Securities Group LLC acquired a new stake in shares of Hims & Hers Health in the 4th quarter worth $38,000. Institutional investors and hedge funds own 63.52% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.